Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2– advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)
The updated results from this study further confirm the real-world effectiveness of palbociclib plus ET in routine clinical practice in Japan. More than 5 years of median OS in 1L was observed, supporting the use of palbociclib plus ET as 1L standard of care for HR+/HER2- ABC.
Authors
- Michiko Harao (ORCID: https://orcid.org/0000-0002-3138-062X)
- Natsuko Mori
- Takuho Okamura (ORCID: https://orcid.org/0000-0002-6014-6736)
- Hiroshi Yoshino (ORCID: https://orcid.org/0000-0003-2656-1482)
- Shinsuke Sasada (ORCID: https://orcid.org/0000-0003-1623-869X)
- Takahiro Nakayama (ORCID: https://orcid.org/0000-0002-3713-1624)
- Masaya Hattori (ORCID: https://orcid.org/0000-0002-0935-9269)
- Nobuyoshi Kosaka (ORCID: https://orcid.org/0000-0001-5571-261X)
- Michiko Tsuneizumi
- Hiroko Masuda (ORCID: https://orcid.org/0000-0002-4306-1298)
- Madoka Iwase (ORCID: https://orcid.org/0000-0002-4423-4023)
- Kenichi Watanabe
- Tetsuhiro Yoshinami (ORCID: https://orcid.org/0009-0000-8747-3641)
- Yasuaki Muramatsu (ORCID: https://orcid.org/0009-0005-4339-2280)
- Daisuke Takabatake (ORCID: https://orcid.org/0000-0002-0359-4890)
- Norikazu Masuda (ORCID: https://orcid.org/0000-0002-7302-0278)
- Manabu Futamura (ORCID: https://orcid.org/0000-0001-5622-8352)
- Hiroyuki Yasojima (ORCID: https://orcid.org/0009-0005-3729-1520)
- Takafumi Sangai (ORCID: https://orcid.org/0000-0003-2052-0479)
- Takanori Ishida (ORCID: https://orcid.org/0000-0003-4565-4721)
- Miki Yamaguchi (ORCID: https://orcid.org/0000-0002-6897-697X)
- Shigenori E. Nagai (ORCID: https://orcid.org/0000-0003-2887-6066)
- Chiya Oshiro
Institutions
- Hiroshima University (JP)
- SHOWA Medical University (JP)
- Toho University (JP)
- Tokai University (JP)
- Jichi Medical University (JP)
- Tohoku University (JP)
- Kyoto University (JP)
- Osaka National Hospital (JP)
- Nagoya University Hospital (JP)
- National Hospital Organization Hokkaido Medical Center (JP)
- Gifu University Hospital (JP)
- Ishikawa Prefectural Central Hospital (JP)
- Saitama Cancer Center (JP)
- Seirei Hamamatsu General Hospital (JP)
- Aichi Cancer Center (JP)
- Shizuoka General Hospital (JP)
- Shikoku Cancer Center (JP)
- Pfizer (Japan) (JP)
- Osaka International Cancer Institute (JP)
- Takarazuka City Hospital (JP)
- Sapporo National Hospital (JP)
- Kitasato University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Breast Cancer
- Published
- 2025-04-05
- DOI
- https://doi.org/10.1007/s12282-025-01689-4
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Pfizer
- Pfizer Japan